Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.47 |
| ▸ | CRHR1 | P34998 | 6/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 2/20 | 0.45 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.45 |
| ▸ | MERTK | Q12866 | 1/20 | 0.45 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.45 |
| ▸ | PLK4 | O00444 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.45 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.45 |
| ▸ | STK16 | O75716 | 1/20 | 0.45 |
| ▸ | STK10 | O94804 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24405365 | 0.85 | LMNA (0.56) | KDM4EALDH1A1HPGDCNR2 | |
| SCHEMBL24405601 | 0.85 | LMNA (0.56) | KDM4EALDH1A1HPGDCNR2 | |
| SCHEMBL24405594 | 0.83 | TAS1R3 (0.57) | CRHR1CRHR2 | |
| SCHEMBL24405480 | 0.83 | TAS1R3 (0.57) | CRHR1CRHR2 | |
| SCHEMBL24406137 | 0.79 | TAS1R3 (0.52) | CRHR1CRHR2 | |
| SCHEMBL30419263 | 0.77 | SMYD3 (0.69) | — | |
| SCHEMBL18010687 | 0.76 | ACKR3 (0.55) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL4418180 | 0.75 | NUAK1 (0.62) | SSTR4KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL13162889 | 0.75 | NPC1 (0.53) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL19028031 | 0.74 | CNR2 (0.54) | CRHR1CRHR2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. | 2024-09-12 | — | — | US | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | SETD2, CARM1, SETDB1 | SSTR4 4381/4885KDM4E 916/4885ALDH1A1 4158/4885 |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | EZH2, HDAC2, SETD2 | SSTR4 4386/4885KDM4E 288/4885ALDH1A1 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.